Show notes
Central line-associated bloodstream infection (CLABSI) prevention efforts in the acute care setting have reduced national CLABSI rates by 50% over the past 20 years. This increase in patient safety in acute care settings is commendable; however, in the home infusion setting, there is currently no standardized definition for CLABSI, no reporting mechanism, or mandatory reporting required for CLABSI. This is significant in that currently1.24 million courses of home infusion therapy are delivered via central vascular access devices (CVADs) to 829,000 patients each year in the U.S. More importantly, home infusion therapy is increasing at a rate of 8% annually. Listen as Dr. Sara Keller discusses collaborative work to help define CLABSI in the home infusion setting which will foster surveillance methodology and improvement processes in this burgeoning patient care environment.

